Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1261-1270

  Masunaga, Shin Ichiro ^a   Uto, Yoshihiro ^b   Nagasawa, Hideko ^b   Hori, Hitoshi ^b   Nagata, Kenji ^a   Suzuki, Minoru ^a   Kinashi, Yuko ^a   Ono, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Misonidazole; Nimorazole; p53 status; Quiescent cell; Radio sensitizer; Repair inhibiting agent; SR 2514

Indexed keywords

BROXURIDINE; MISONIDAZOLE; NIMORAZOLE; PROTEIN P53; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CELL POPULATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CELL SUSPENSION; CLONOGENESIS; DRUG ACTIVITY; DRUG EFFECT; GAMMA RADIATION; GENE MUTATION; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; COMBINED MODALITY THERAPY; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GAMMA RAYS; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MISONIDAZOLE; NIMORAZOLE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645812558     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Zackrisson B, Mercke C, Strander H, Wennerberg J and Cavallin-Stahl E: A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42: 443-461, 2003.
2. Fei P and El-Deiry WS: P53 and radiation responses. Oncogene 22: 5774-5783, 2003.
3. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M and Alt FW: DNA repair, genome stability, and aging. Cell 120: 497-512, 2005.
4. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
5. Steele RJ and Lane DP: P53 in cancer: a paradigm for modern management of cancer. Surgeon 3: 197-205, 2005.
6. de Moura Gallo CV, Azevedo E, Silva Mendonca G, de Moraes E, Olivier M and Hainaut P: TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives. Mutat Res 589: 192-207. Epub 2005 Mar 31, 2005.
7. Masunaga S and Ono K: Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J Radiat Res 43: 11-25, 2003.
8. Ota I, Ohnishi K, Takahashi A, Yane K, Kanata H, Miyahara H, Ohnishi T and Hosoi H: Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma. Int J Radiat Oncol Biol Phys 47: 495-501, 2000.
9. Takahashi A: Different inducibility of radiation- or heat-induced p53-dependent apoptosis after acute or chronic irradiation in human cultured squamous cell carcinoma cells. Int J Radiat Biol 77: 215-224, 2001.
10. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R and Kuroki T: Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19: 243-253, 1997.
11. Ohnishi K, Wang X, Takahashi A and Ohnishi T: Contribution of protein kinase C to p53 dependent WAF1 induction pathway after heat treatment in human glioblastoma cell lines. Exp Cell Res 238: 399-406, 1998.
12. Masunaga S, Ono K, Takahashi A, Ohnishi T, Kinashi Y and Takagaki M: Radiobiological characteristics of solid tumours depending on the p53 status of tumour cells, with emphasis on the response of intratumour quiescent cells. Eur J Cancer 38: 718-727, 2002.
13. Adams GE, Clark ED, Flockart IR, Jacobs RS, Sehmi DS, Stratford IJ, Wardman P, Watts ME, Parrick J, Wallace RG and Smithen CE: Structure-activity relationships in the development of hypoxic cell sensitizers: I. Sensitization efficiency. Int J Radiat Biol 35: 133-150, 1979.
14. Adams GE, Clark ED, Gray P, Jacobs RS, Stratford IJ, Wardmam P, Watts ME, Parrick J, Wallace RG and Smithen CE: Structure-activity relationships in the development of hypoxic cell sensitizers: II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol 35: 151-160, 1979.
15. Overgaard J: Sensitization of hypoxic tumor cells. Clinical experiences. Int J Radiat Biol 56: 801-811, 1989.
16. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, Berthelsen A, Hammer R and Pedersen M: Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA study. Int J Radiat Oncol Biol Phys 16: 1065-1068, 1989.
17. Overgaard J, Eriksen JG, Nordsmark M, Aisner J and Horsman MR: Danish Head and Neck Cancer Study Group: Plasma osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomized double-blind placebo-controlled trial. Lancet Oncol 6: 757-764, 2005.
18. Sigal A and Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793, 2000.
19. Vousden KH and Prives C: P53 and prognosis: new insights and further complexity. Cell 120: 7-10, 2005.
20. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M and Giaccia A: Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21: 1297-1310, 2001.
21. Hammond EM, Dorie MJ and Giaccia AJ: ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 278: 12207-12213, 2003.
22. Soussi T and Lozano G: p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331: 834-842, 2005.
23. Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998.
24. Vaupel P, Kelleher DK and Hoeckel M: Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28(Suppl 8): 29-35, 2001.